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Background: Cronobacter spp. are opportunistic pathogens that can cause septicemia and infections of the central
nervous system primarily in premature, low-birth weight and/or immune-compromised neonates. Serum resistance
is a crucial virulence factor for the development of systemic infections, including bacteremia. It was the aim of the
current study to identify genes involved in serum tolerance in a selected Cronobacter sakazakii strain of clinical
origin.
Results: Screening of 2749 random transposon knock out mutants of a C. sakazakii ES 5 library for modified serum
tolerance (compared to wild type) revealed 10 mutants showing significantly increased/reduced resistance to serum
killing. Identification of the affected sites in mutants displaying reduced serum resistance revealed genes encoding
for surface and membrane proteins as well as regulatory elements or chaperones. By this approach, the
involvement of the yet undescribed Wzy_C superfamily domain containing coding region in serum tolerance was
observed and experimentally confirmed. Additionally, knock out mutants with enhanced serum tolerance were
observed. Examination of respective transposon insertion loci revealed regulatory (repressor) elements, coding
regions for chaperones and efflux systems as well as the coding region for the protein YbaJ. Real time expression
analysis experiments revealed, that knock out of the gene for this protein negatively affects the expression of the
fimA gene, which is a key structural component of the formation of fimbriae. Fimbriae are structures of high
immunogenic potential and it is likely that absence/truncation of the ybaJ gene resulted in a non-fimbriated
phenotype accounting for the enhanced survival of this mutant in human serum.
Conclusion: By using a transposon knock out approach we were able to identify genes involved in both increased
and reduced serum tolerance in Cronobacter sakazakii ES5. This study reveals first insights in the complex nature of
serum tolerance of Cronobacter spp.
Keywords: Cronobacter sakazakii ES5, Clinical isolate, Serum tolerance, Tn5-mutagenesis, Identification, PCR,
Complementation, Expression analysisBackground
The genus Cronobacter, member of the family Entero-
bacteriaceae, comprises seven species – C. sakazakii, C.
turicensis, C. malonaticus, C. muytjensii, C. dublinensis, C.
universalis and C. condimenti [1,2]. They are opportunistic
pathogens that can cause septicaemia and infections of the
central nervous system primarily in premature, low-birth
weight and/or immune-compromised neonates [3]. Most* Correspondence: lehnera@fsafety.uzh.ch
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reproduction in any medium, provided the oroutbreaks have been reported in neonatal intensive care
units where the sources of infection have been traced to
Cronobacter spp. contaminated, reconstituted powdered
infant formula (PIF) and/or feeding equipment.
As a foodborne pathogen causing systemic infections,
Cronobacter spp. must cross the gastrointestinal barrier
and, following their tropism for the central nervous system,
translocate to and cross the blood–brain barrier (BBB). In
that context, it is expected that Cronobacter spp. express
virulence factors that help in colonization and invasion of
mucosal cells [4] as well as effectors that confer the ability
of Cronobacter spp. to overcome the mechanisms of killingal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Sensitivity of C. sakazakii ES5 transposon insertion
mutants during incubation in 50% HPS for 60 min and 120 min
compared to the wt. Within this graph results are depicted which
were generated during the confirmative serum sensitivity tests on
mutants selected during the screening procedure in the 96 well format.
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system [5,6].
Microbes that cause invasive infections have evolved
strategies to protect themselves against the bactericidal
action of the serum/complement. Structures of the bacterial
cell surface, such as capsules, LPS and outer-membrane
proteins have been identified as being responsible for the
complement resistance of bacteria [6,7]. For Cronobacter
spp. it has been shown, that the outer membrane protein
Omp A contributes significantly to the survival of the
bacteria in the blood [8].
In a more recent study an outer membrane protease Cpa
has been identified as a factor that activates plasminogen,
thus mediating serum resistance in C. sakazakii [9]. How-
ever, it has been demonstrated, that there is a considerable
degree of variation among Cronobacter spp. isolates with
respect to their ability to resist serum complement [10]. In
a pilot study a set of Cronobacter isolates (all species,
subspecies) from various origins (clinical, environment,
milk powder) was tested for their capacity to survive in
human blood and the clinical isolate Cronobacter sakazakii
ES5 was identified as the most tolerant strain (i.e. ≤ 2 log
reduction during incubation in 50% human pooled serum
for 120 min) among the Cronobacter sakazakii isolates
tested (data not shown).
This strain was selected for further experiments
aiming for the identification and analysis of genes
involved in this feature.
Results and discussion
Identification of genes involved in modified serum
tolerance in C. sakazakii
Screening of 2749 random mutants from a C. sakazakii
ES5 Tn5 library for modified serum tolerance revealed
10 candidates for which a significantly increased/reduced
tolerance to serum killing (as compared to the wild type)
was confirmed. In Figure 1 the variations in the survival
of the mutants expressed as log variation (y-axis) over
time (x-axis) is depicted. Serum sensitivity was expressed in
log variations (number of cfu ml-1 after incubation in
50% human pooled serum (HPS) for 60 and 120 min
(T60, T120)/ the number of cfu ml
-1 of non- serum
exposed inoculum (T0). By referring the counts after
incubation to T0, the inoculum variations were corrected
for all experiments.
Only mutants for which a single transposon insertion in
the chromosome was confirmed were subjected to the
subsequent mapping experiments. The sequences obtained
were subjected to similarity searches at the NCBI website.
Table 1 summarizes the affected coding regions for the
mutants, the closest homologue on the amino acid level
and description of the putative function of the protein.
Identification of the respective mutated sites from
mutants displaying reduced serum resistance includedgenes coding for surface and membrane proteins (67.1,
BF4), (transcription) regulatory genes (51_C4, 51_C6) as
well as a DnaJ domain containing protein (69_F1).
Mutant 67_1 represents a knock out in the igaA coding
gene. This non-pigmented mutant has been identified in
the study by Johler et al. (2012) but was not subject of
further investigation in this study [11]. However, this
protein was identified in Salmonella Typhimurium as a
membrane protein that attenuates the response of the
RcsCDB signalling system to environmental stress.
The Rcs two component system is known to be
involved in the (positive/negative) regulation of a
number of target genes including biofilm formation
and pathogenicity. Thus, it has been reported, that
the constitutive activation of this system dramatically
attenuates Salmonella virulence [12].
Mutant BF4 was originally described in the study by
Hartmann et al. (2010) where it was found to produce
less biofilm on polystyrene [13]. The transposon inser-
tion affected a site with 100% homology to the locus
ESA_04103 of the C. sakazakii ATCC BAA 894 genome
(CP000783.1) to which the annotation hypothetical
protein was available at that time. However, BLASTx
analysis of the respective protein reveals homology to
proteins containing a conserved Wzy_C superfamily
domain. The coding region for this protein must not be
confused with the gene for the Wzy protein which is
part of the O- antigen gene locus (often referred to as
rfb locus in Enterobacteriaceae) located between
ESA_01177 and ESA_01190 the function of which is
annotated as O-antigen polymerase. The O-antigen
forms part of the lipopolysaccharide (LPS) in the outer
membrane of Gram-negative bacteria and is one of the
most variable constituents on the cell surface. There are
Table 1 Identification and description of affected insertion sites in mutants displaying modified serum resistance in
C. sakazakii ES5
Annotation
Mutant Phenotype Locus tag closest
homologue blastx/organism
Protein Name
(max ident aa)
Description
67.1a Reduced serum
resistance
ESA_04343/Cronobacter
sakazakii BAA-894
Putative uncharacterized
protein (100%)
Putative membrane protein IgaA homolog
(C. turicensis z3032)
BF4b Reduced serum
resistance
ESA_04103/Cronobacter
sakazakii BAA-894
Putative uncharacterized
protein (100%)
Hypothetical protein, conserved domain: Wzy_C
superfamily O-antigene ligase
51_C4c Reduced serum
resistance
ESA_03258/Cronobacter
sakazakiiBAA-894
DNA binding transcriptional
regulator FruR (99%)
Fructose repressor
51_C6c Reduced serum
resistance
CSE899_07155/Cronobacter
sakazakii E899
Hypothetical protein (100%) FadR, GNTR family of transcriptional regulator, winged
helix-turn helix DNA binding domain.
69_F1c Reduced serum
resistance
ESA_01368 Cronobacter
sakazakii BAA-894
Hypothetical protein (98%) DnaJ domain protein
1_E1c Increased serum
resistance
CSE899_13864 Cronobacter
sakazakii E899
Copper homeostasis protein
CutC (100%)
Uncharacterized protein involved in copper resistance
4_G12c Increased serum
resistance
ESA_03283 Cronobacter
sakazakii ATCC BAA-894
Hypothetical protein (99%) DjlA
21_G1c Increased serum
resistance
ESA_02809/Cronobacter
sakazakii BAA-894
Hypothetical protein (99%) Hha toxicity attenuator, YbaJ “biofilm formation regulator”
C. sakazakii E899
24_H4c Increased serum
resistance
ESA_03832/Cronobacter
sakazakii BAA-894
Hypothetical protein (100%) ribonuclease activity regulator protein RraA
37_A11c Increased serum
resistance
Ctu_3p00270/ Cronobacter
turicensis z3032
Hypothetical protein (99%) On Plasmid pCtu3 of C. turicensis z3032 – no annotation
available
a obtained from the study by Johler et al., 2010 [11].
b obtained from the study by Hartmann et al., 2010 [13].
c this study.
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described for C. sakazakii and the putative organization
of the genes included in the different clusters has been
published recently [14,15]. As in one of these serotypes
(O7), the wzy gene does not seem to be part of the
cluster it has been proposed, that a different, yet
unknown gene mapping elsewhere in the chromosome
may code for this essential function and we further
hypothesized that the ESA_04103 coding region may
have been a candidate for this. However, determination
of the O-antigen serotype of the C. sakazakii ES5 strain by
application of a recently developed PCR based serotyping
scheme [16] revealed that this strain belongs to the O2
serotype (data not shown).
As to date there is no experimental data on the involve-
ment of the ESA_04103 coding region in serum tolerance
available, we aimed to investigate whether an intact copy of
the ESA_04103 gene provided in trans to the ESA_04103
deleted mutant BF4 would restore the serum tolerance to
wild type level. Therefore this gene including its putative
native promoter region was cloned onto a low copy
expression vector and the resulting construct was
transformed into BF4 mutant. Serum sensitivity tests were
performed using the C. sakazakii ES5 wt strain, the BF4
(ΔESA_04103) mutant, the BF4 (ΔESA_04103) mutant
containing an empty pCCR9 vector (BF4_pCCR9) and thecomplemented mutant BF4_pCCR9::ESA_04103. The
results of these experiments are depicted in Figure 2. An
inactivation around 5 log during incubation in 50% human
serum for 120 min was observed in the BF4
(ΔESA_04103) mutant as well as the mutant containing
the low copy vector pCCR9, whereas the survival of the
mutant with supplied vector pCCR9 and ESA_04103 was
restored to 4 log reduction cfu ml-1 compared to T0
compared to the wt with 1.2 log reduction. We could,
however, not completely restore the serum survival to wild
type levels in the complemented mutant. This may be
explained (in part) by the unknown copy number of the
mRNA for this gene in the wild type during incubation in
serum and/or by possible polar effects.
Mutant 69_F1 was identified to be affected in a gene
coding for a DnaJ domain family protein. Members of
this family are essential for their interaction with DnaK
chaperone and activation of its ATPase activity. In
Edwardsiella tarda it was recently demonstrated that
DnaJ and DnaK play a crucial role in general bacterial
virulence, in blood dissemination capacity [16].
Interestingly, by using the Tn5 approach we found an
equally high number of knock out mutants, that showed
an enhanced survival in human serum compared to the
wild type. One of the obvious possibilities to explain this
phenomenon would be the knock out of regulatory
Figure 2 Serum sensitivity test on C. sakazakii ES5 wt, mutant
BF4 (ΔESA_04103), mutant containing the empty vector
(BF4_pCCR9) and mutant complemented with the intact
ESA_04103 gene (BF4_pCCR9::ESA_04103) after incubation in
50% HPS for 120 min (T120). The means and standard deviations
(±1SD) from two independent experiments are presented. An
asterisk above the bars indicate statistically significant differences.
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activation/constitutive expression of the respective
phenotype. Mutant 24_H4 (ΔrraA) may fall into this
category. The region affected by the transposon in this
mutant shows homology to the ribonuclease regulator
protein RraA. This protein acts as an inhibitor of the es-
sential endoribonuclease RNase E, which itself plays a
crucial role in global mRNA metabolism as well as in
the maturation of functional RNAs such as rRNAs,
tRNAs, tmRNA, and small regulatory RNAs [17-20].
However, Lee et al. [21] demonstrated that ectopic
expression of RraA itself affects the abundance of more
than 700 transcripts in Escherichia coli, thus making it
difficult to hypothesize upon the influence of the knock
out of this gene on the enhanced survival of the mutant
in human serum.
More surprising was the finding that deletions in genes
putatively coding for (co-)chaperones lead to an enhanced
survival in human serum. One of those, namely 4_G12
(ΔdjlA), is a member of the J-domain protein family. DjlA
can substitute for DnaJ co-chaperone [22] and seems to
have multiple functions. However, it has also been
described that DjlA negatively regulates the response of
the two component RcsCDB signaling system to envelope
stress. The Rcs signal transduction system positively
regulates the expression of many different genes among
those are the ones forming the capsular polysaccharide
synthesis operon (cps) [23]. The expression of capsules
may provide protection from serum killing components
(see above). In a study by Shiba et al. [24] it was
demonstrated that djlA deletion resulted in increasedactivation of the Rcs system. This might positively regulate
cps transcription.
Mutant 21_G1 (ΔybaJ) exhibiting an enhanced serum
tolerance was shown to be affected in a gene coding for
the YbaJ protein. It has been proposed that YbaJ and its
adjacent protein Hha may form a so called toxin-antitoxin
pair where YbaJ (antitoxin) negatively regulates the
expression of Hha (toxin), the latter one (among other
functions) serving as a repressor for type 1 fimbriae [25].
Type 1 fimbriae are highly immunogenic, thus a strain not
expressing these structures may have an advantage in
survival during exposure in human serum [26].
In the present study we further examined the hypothesis
that the disruption of the regulatory gene ybaJ may lead to
an activation of the Hha protein which in turn would
negatively influence transcription of the key fimbrial struc-
tural gene fimA. RT-qPCR experiments were performed in
order to quantify hha and fimA mRNA levels in the C.
sakazakii ES5 wt and mutant 21_G1(ΔybaJ) strains, before
and after exposure to human serum. The levels of fimA
mRNA were more than 4.5 log lower in the mutant
21_G1(ΔybaJ) strain compared to the C. sakazakii ES5 wt
strain. The hha mRNA levels were for the mutant
compared to the wt 5 log lower and not like expected
higher, suggesting that the deletion of the ybaJ gene did
not result directly in a de-repression/ activation of the hha
gene in our experimental set up (Figure 3). Our results
rather suggest that ybaJ itself may be involved in the regu-
lation/activation of the expression of the type 1 fimbriae
in C. sakazakii.
Conclusions
By using a transposon knock out approach we were able to
identify structural and regulatory genes in Cronobacter
sakazakii ES5, deletion of which resulted in a dramatically
reduced capability to survive in serum. Additionally, several
mutants were found displaying an enhanced survival in
serum as compared to the wild type. Analysis of the genetic
elements possibly responsible for this phenotype revealed
genes coding for chaperone-like proteins, regulatory
(repressor) elements as well as genes for structures or
components representing immunogenic targets. The dele-
tion of the ybaJ element which is part of the antitoxin-toxin
pair YbaJ-Hha resulted in an abolished expression of a key
element of the type 1 fimbriae. The absence of the latter
most likely accounted for the enhanced survival of this
mutant in human serum.
Methods
Bacterial strains and culture conditions
Cronobacter sakazakii strain E5, a clinical strain was
used in this study. Wild type and mutant strains, E. coli
DH5 alpha as well as plasmids and primers that were
included and constructed during the transposon library
Figure 3 Relative levels of hha and fimA mRNA in control (T0) and serum treated (T120) C. sakazakii ES5 wt and mutant 21_G1 (ΔybaJ)
cells. RNA was isolated from mid exponential growth stage cells prior (T0) and after (T120) human serum exposure. Values were normalized using
16S rRNA as a reference gene. The means and standard deviations (±1SD) from three independent experiments are presented. An asterisk above
the bars indicate statistically significant differences in mRNA levels between the C. sakazakii ES5 wt and mutant (P < 0.05).
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the expression (21_G1) experiments are summarized
in Table 2. All strains were incubated at 37C in
Luria–Bertani (LB) broth, over night with gentle shaking.
When appropriate, antibiotics were used at the following
concentrations: kanamycin at 50 μg ml-1 and tetracyclin
at 50 μg ml-1.
Identifcation of transposon mutants modulating serum
tolerance in Cronobacter sakazakii ES 5
A random transposon mutant (EZ-Tn5 <KAN-2 >Tnp)
library of the clinical isolate Cronobacter sakazakii ES5
[11,13] was screened for modified (i.e. significant log
variation in survival during exposure compared to wild
type) survival in 50% human pooled serum (HPS) over a
period of 120 min. For these experiments, the mutants
were grown in 96 well microtiterplates overnight in LB
supplemented with 50 μg/ml kanamycin at 37C. Ten μl of
these overnight cultures were transferred into a 96 well
screening plate containing 50 μl HPS and 40 μl 0.9% NaCl
per well and incubated for 120 min at 37C (T120).
Concentrations of bacterial cultures were determined by
OD590nm measurement at T0 and T120 and compared to
respective wild type measurements. Thresholds of (1) more
than 2 times reduction and (2) more than 7 times increase
of OD value during incubation for 120 min relative to the
wild type values were set in order to identify potential
candidates which were subsequently subjected to a
confirming serum sensitivity test.
Confirmative serum sensitivity tests
LB grown overnight cultures were diluted 1:20 in 10 ml
LB and allowed to grow at 37C to OD590nm = 0.5. Cells
were washed twice in 0.9% NaCl, resuspended in 5 ml
0.9% NaCl and diluted to 10-2. These dilutions (= 100)
served as inoculum for the experiments in 50% humanserum. Concentrations of bacterial inoculations at T0
were determined by plating 100 ul of 10-3, 10-4 and 10-5
dilutions of the inoculum on LB plates and enumeration
of CFU after incubation at 37C overnight. Two hundred
fifty μl HPS was mixed with 50 μl of the above
mentioned dilution (100, approx. 106 CFU ml-1) and
200 μl of 0.9% NaCl and incubated at 37C. Survival of
the bacterial cells during incubation in 50% HPS was
followed by plate count enumeration (plating of 100 ul
of a dilution series 10-1 – 10-5) after 60 and 120 min
(T60, T120). Sensitivity during exposure was expressed in
log reduction rates as number of bacteria that survived
treatment/number of bacteria in non – serum- exposed
inoculum = T0). The activity of the human pooled serum
(HPS) used for the experiments was tested by comparing
cfu ml-1 determined after incubation of C. sakazakii E5
strain in 50% native or heat inactivated (56C for
30 min) HPS for 120 min for each new batch (batch
control, data not shown).
During serum sensitivity tests on (pCCR9 vector
containing) mutants BF4_pCCR9 and BF4_pCCR9::
ESA_04103, the serum as well as the plate count
medium for enumeration was supplemented with
kanamycin and tetracycline both at 50 μg ml-1.
Identification of transposon insertion sites
All kits for DNA isolation and purification were obtained
from Qiagen (Hilden, Germany) and handled by following
the manufacturer’s instructions. Unless otherwise stated,
chromosomal DNA was isolated using the DNeasy Blood
and Tissue kit. Plasmids were extracted with the QIAprep
Spin Miniprep or Plasmid Midi kits. DNA fragments from
PCRs, restriction digests, and agarose gels were purified
using the MinElute PCR Cleanup kit and the MinElute
Gel Purification kit, respectively. The concentration of
nucleic acids was determined using a Nanodrop ND-1000
Table 2 Material used in this study
Strains/plasmids/primers Genotype/characteristic(s)/sequences Source or reference
Strains
Cronobacter sakazakii
ES5 (wild type) Human isolate Hartmann et al., 2010, Johler et al., 2010 [11,13]
BF4 (mutant) ΔESA_04103, KanR Hartmann et al., 2010 [13]
BF4_pCCR9 BF4 harboring pCCR9, KanR, TetR This study
BF4_pCCR9::ESA_04103 BF4 harboring pCCR9:: ESA_04103, KanR, TetR This study
21_G1 (mutant) ΔybaJ, KanR This study
Escherichia coli DH5 alpha F– Φ 80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17
(rK–, mK+) phoA supE44 λ– thi-1 gyrA96 relA1
Epicentre
Plasmids
pUC19 High copy cloning/expression vector AmpR Epicentre
pCCR9 Low copy cloning/expression vector, TetR Randegger et al., 2000 [28]
pCCR9::ESA_04103 pCCR9::ESA_04103, TetR This study
Primer for sequencing
KAN-2FP1 50-ACC TAC AAC AAA GCT CTCATC AAC C-30 Epicentre
pCCR9-F 50-TTT GAC AGC TTA TCA TCG-3 This study
pCCR9-R 50-CCT ATG GAA GTT GAT CAG-3 This study
Primer for complementation
BF4f1 50-GAC GCC AAG CTT GCG CGA GCC TGC GTT TAA-30 This study
BF4r2 50- AGT CTG GGA TCC AAA CAT TAT CCT TCT TTA TAG-30 This study
Target/primer for expression
ybaJf 50-CGG CAT GAT ATA GCG CAG-30 This study
ybaJr 50-GAT GTG TAT AAG AGA CAG-30 This study
hhaf 50-CAA ACC ATT AAC CAA AAC CG-30 This study
hhar 50-CGG AAT TTT ATC GTA GAG CTT-30 This study
fimAf 50-AAA CCG CGT TTA CTG G-30 This study
fimAr 50-GCA ACG GAG TTT GCT T-30 This study
16S rRNAf 50-GTG TTG TGA AAT GTT GGG T-30 This study
16S rRNAr 50-ACT AGC GAT TCC GAC TT-30 This study
1 Primer sequence is underlined, recognition site for restriction enzyme Hind III is given in bold.
2 Primer sequence is underlined, recognition site for restriction enzyme Bam HI is given in bold.
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Wilmington, DE). Mutants with confirmed phenotype
were further subjected to Southern blot analysis in order
to determine the chromosomal transposon copy number
[11]. Only mutants for which a transposon copy number
of one was confirmed were subject of further analysis.
Mapping of transposon insertion sites using a subcloning
approach was performed as described previously [11]. In
brief, chromosomal DNA of the transposon mutants was
digested with SphI. The fragments were ligated into
pUC19 (Table 2) digested with the same enzyme. After
ligation (12 h at 16C) the construct was electroporated
into E. coli DH5 alpha (Table 2). Transformants carrying a
plasmid containing the transposon (= kanamycin cassette)
were identified by plating the transformants on LBsupplemented with kanamycin. Plasmids were extracted
from the selected clones, and the transposon-flanking
regions were sequenced with primer KAN-2 FP1 (Table 2).
Transposon insertion sites were determined by sequencing
the junctions between the Tn5 transposon sites and the
ES5 chromosomal DNA. All sequencing was outsourced
(Microsynth, Balgach, Switzerland). The sequences
obtained from each mutant were determined by similarity
search using BLASTn and BLASTx at the NCBI website
http://blast.ncbi.nlm.nih.gov/Blast.cgi [27]. The original
nucleotide sequences obtained for the mutants after se-
quencing are provided as supplementary data (Additional
file 1).
The cloning, restriction enzyme analysis, and transfor-
mation of C. sakazakii were performed using standard
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from Roche (Basel, Switzerland) or New England Biolabs
(Ipswich, MA).
Complementation experiment with serum sensitive
mutant and BF4 (ΔESA_04103)
The ESA_04103 locus was amplified using primer pair
BF4f and BF4r (Table 2). This primer pair was designed
based on the whole genome sequence of Cronobacter
sakazakii BAA-894 (CP000783.1) spanning the region
from 4058124 to 4059648, including the putative coding
sequence as well as 220 bp upstream of the open reading
frame in order to ensure the inclusion of the native
promoter. The amplification mix contained 0.4 μM of
primers, 1 x AccuPrime (Invitrogen) buffer 2 (60 mM
Tris-SO4 (pH 8.9), 18 mM (NH4)2SO4, 2 mM MgSO4,
2 mM dGTP, 0.2 mM dATP, 0.2 mM dTTP, 0.2 mM
dCTP, thermostable AccuPrimeTM protein, 1% glycerol)
and 2 U AccuPrime Taq DNA Polymerase High Fidelity
(Invitrogen). Following PCR conditions were used: 94C
for 30 s followed by 35 cycles of 94C for 30 s, 54C for
30 s and 68C for 120 s.
The resulting PCR products were double digested with
the restriction enzymes Hind III and Bam HI and cloned
into the low copy vector pCCR9 [28] which had been
digested with the respective enzymes to create the comple-
mentation vector pCCR9::ESA_04103. The construct was
transformed into the BF4 mutant strain by electroporation
and transformants were selected on LB agar supplemented
with kanamycin and tetracycline. The correct insertion of
the desired fragment was confirmed by amplification and
sequencing of the insert of a complemented BF4 mutant
using primers located on the pCCR9 vector (pCCR9-F and
pCCR9-R, Table 2) and employing the conditions as
described during the complementation cloning approach.
The sequence of the insert is provided in Additional file 1.
Additionally a BF4 mutant containing the pCCR9 vector
(BF4_pCCR9) only (no insert) was created and used to-
gether with the complemented strain BF4_pCCR9::
ESA_04103 in the serum sensitivity assay as described
above. The serum assays were carried out in duplicates
(= two independent experiments).
Serum exposure and RNA purification
An 0.5 ml aliquot of a stationary phase grown culture of
the wt and mutant strain was used to inoculate 10 ml of
LB and grown to the mid exponential growth stage
(OD590nm = 0.5) at 37C. Cronobacter cells were washed
twice in 10 ml and finally resuspended in 5 ml of 0.9%
NaCl solution. Two and half milliliters of the resuspended
Cronobacter cells were mixed with 12.5 ml HPS and 10 ml
0.9% NaCl. Aliquots of 10 ml were promptly collected.
The mixtures were incubated for 120 minutes at 37C and
a second set of aliquots was collected. RNA profiles incollected aliquots were promptly preserved using the bac-
terial RNA Protect Reagent (Qiagen). Cronobacter cell
pellets were immediately processed or frozen at −70C for
total RNA extraction at a later stage. Total RNA was
isolated using the Qiagen RNeasy Plus Mini kit (Qiagen)
with minor modifications to the original kit protocol.
Cronobacter cells resuspended in 0.5 ml RNeasy Plus Mini
Kit lysis buffer (Qiagen) were transferred on to the lysing
bead matrix in MagNA lyser tubes and mechanically
disrupted in the MagNA Lyser Instrument (Roche
Molecular Diagnostics). Two DNA removal steps were
incorporated by using a genomic DNA binding column
included in the RNeasy Plus Mini Kit as well as by
performing an in-column DNAseI (RNase-Free DNase;
Qiagen) digestion of the samples bound to the RNA spin
column. Total RNA was eluted from the column into
30 μl of RNAse-free water. RNA yields were determined
using the Nanodrop ND-1000 spectrophotometer (Nano
Drop Technologies, Wilmington, DE). RNA quality was
assessed using the Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA). Purified RNA was
immediately frozen −70C for long-term storage.DNA synthesis and quantitative real time PCR
The synthesis of cDNA was performed using the
Quantitect Reverse Transcription Kit (Qiagen). One
microgram of total RNA was reverse transcribed to cDNA
in 20 μl. Generated cDNA was amplified by quantitative
real-time PCR using the Light Cycler 480 instrument
(Roche Molecular Diagnostics, Rotkreuz, Switzerland).
Primers used for the amplification of the target (hha and
fimA) and reference (16S rRNA) genes are listed in Table
2. Primers were designed using the LC probe design soft-
ware (Roche Molecular Diagnostics, Penzburg, Germany).
Quantitative real-time PCR mixtures contained Light
Cycler R 480 SYBR Green I Master (5 μl), forward and
reverse primer mixture (2.5 μl) and 100 ng of the cDNA
template (2.5 μl). The PCR cycling conditions were
as previously described [29]. Reference gene validation
was performed as previously described [30], and this
established that 16S rRNA mRNA levels were suit-
able for normalization of relative mRNA quantifica-
tion under experimental conditions of the present
study. The hha and fimA mRNA levels were quanti-
fied relative to the 16S rRNA reference gene and the
Light Cycler 480 Relative Quantification Software
(Roche Molecular Diagnostics). The relative hha and
fimA mRNA levels obtained after normalization were
log converted and data shown are based on the
means and standard deviations from three indepen-
dent assays. The statistical significance of differences
in hha and fimA mRNA levels between Cronobacter
wt and mutant strains were analyzed using t-tests,
Schwizer et al. BMC Microbiology 2013, 13:38 Page 8 of 8
http://www.biomedcentral.com/1471-2180/13/38and P-values <0.05 were considered to be statistically
significant.
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